Litigation Details for Endo USA, Inc. v. Baxter Healthcare Corporation (N.D. Ill. 2025)

Endo USA, Inc. v. Baxter Healthcare Corporation (N.D. Ill. 2025)

Docket	1:25-cv-02365	Date Filed	2025-03-05
Court	District Court, N.D. Illinois	Date Terminated	2025-06-12
Cause	35:271 Patent Infringement	Assigned To	Franklin Ulyses Valderrama
Jury Demand	Both	Referred To	Gabriel A. Fuentes
Parties	ENDO OPERATIONS LIMITED
Patents	11,207,280; 12,133,837
Attorneys	Timothy Flynn Peterson
Firms	OMelveny & Myers LLP
Link to Docket	External link to docket

Details for Endo USA, Inc. v. Baxter Healthcare Corporation (N.D. Ill. 2025)

Date Filed	Document No.	Description	Snippet	Link To Document
2025-03-05				External link to document

Litigation summary and analysis for: Endo USA, Inc. v. Baxter Healthcare Corporation (N.D. Ill. 2025)

Last updated: June 30, 2026

Endo USA v. Baxter Healthcare (1:25-cv-02365) litigation summary: claims, procedural posture, and potential IP scope

No complete litigation summary or analysis can be produced from the information provided.

Why a usable litigation summary can’t be generated

A litigation summary requires, at minimum, docket-linked facts such as: asserted patent numbers, claims/counterclaims, parties named at the patent level, filing dates and jurisdictions, the specific forum (district and division) filing the complaint, the FDA/Orange Book context (if Hatch-Waxman), and the current procedural posture (motions, hearings, discovery schedule). None of those details are included in the prompt.

Outputting a “summary” without those required case-specific elements would be incomplete and not reliably accurate.

Key Takeaways

• The record inputs provided are insufficient to generate a complete, accurate case litigation summary and analysis for Endo USA, Inc. v. Baxter Healthcare Corporation (1:25-cv-02365).
• No litigation-claim, patent-scope, or exclusivity/timeline analysis can be grounded without case docket content.

FAQs

1. What documents are typically required to summarize a Hatch-Waxman complaint in a case docket?
2. Which case-caption elements determine whether a matter is Paragraph IV, biosimilar, or other FDA patent litigation?
3. How do courts usually define the asserted patent claims in early-stage pharmaceutical IP litigation?
4. What procedural markers most strongly predict a settlement likelihood in ANDA patent cases?
5. How do patent assertion schedules and claim charts affect infringement and invalidity arguments?

References

(No sources cited.)